Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Izotropic Corp C.IZO

Alternate Symbol(s):  IZOZF

Izotropic Corporation is a Canada-based medical device company. The Company is engaged in the development and commercialization of IzoView, a computed tomography (CT) imaging system, which produces cross-sectional images that can be imaged in the 30 centi-meter aperture by computer reconstruction of x-ray transmission data for non-invasive visualization of tissue. The IzoView is for use in the non-invasive visualization of breast tissue, as an adjunct tool to mammography, by providing x-ray computer reconstructed images as an aid for qualified healthcare providers. The Company has not generated any revenue.


CSE:IZO - Post by User

Post by gunzodon Jan 11, 2021 2:12pm
113 Views
Post# 32268458

news

news
IZOTROPIC GRANTS RESTRICTED AND PERFORMACE SHARE UNITS
 
 
 
 
VANCOUVER, BC – January 11, 2021 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) announces it has issued 1,550,000 Restricted Stock Units (“RSU” or “RSUs”) to advisors, consultants and a director, and 500,000 Performance Stock Units (“PSU” or “PSUs”) to the Company’s Commercial Operations Executive.
 
Further to the Company’s news release dated July 10, 2020, the Company adopted a Long Term Equity Incentive Plan (“LTIP”), wherein the Company may grant up to 10% of the total amount of issued common shares to key individuals as a way of providing long term and performance (milestone) based incentives. The LTIP will be utilized as the Company’s primary tool to reward value-based performance from scientists, advisors and consultants who contribute to making breast CT an indispensable tool for improving the outcomes of breast cancer.
 
The RSUs vest on the following schedule:
 
662,500 RSUs on January 11, 2021;
262,500 RSUs on July 11, 2021;
262,500 RSUs on January 11, 2022;
262,500 RSUs on July 11, 2022;
100,000 RSUs in increments of 50,000 upon completion of milestones related to the development of the Company’s commercial breast CT imaging system
The PSUs vest on the following schedule:
 
225,000 PSUs upon FDA submission;
225,000 upon first sale of the Company’s breast CT imaging system
 
ON BEHALF OF THE BOARD
 
 
Robert Thast
Chief Executive Officer
 
 
Contact Information
 
For investor relations inquiries contact:
Dan Sammartino
Phone: 1-778-962-0234
Email: IR@izocorp.com
 
For general inquiries contact:
Izotropic Corporation
Phone: 1-833-IZOCORP
Email: info@izocorp.com
 
<< Previous
Bullboard Posts
Next >>